DoubleLine ETF Adviser’s Biogen BIIB Stock Holding History

DoubleLine ETF Adviser’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$421K	Sell	1,947 -178	-8%	-$34K	0.17%	127
2026 Q1	$390K	Buy	+2,125	New	+$392K	0.15%	135

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DoubleLine ETF Adviser's BIIB Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its Biogen (BIIB) stake by 8.4% in Q2 2026, selling an estimated $34K and leaving 1,947 shares worth $421K. The position accounts for 0.17% of the portfolio, ranked #127.

DoubleLine ETF Adviser first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

DoubleLine ETF Adviser held 1,947 shares of Biogen worth $421K as of Q2 2026.
DoubleLine ETF Adviser sold 178 Biogen shares in Q2 2026, an estimated $34K.
Biogen made up 0.17% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #127 holding.
DoubleLine ETF Adviser first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.